Johnson & Johnson
JNJ (NYSE)
Johnson & Johnson (JNJ) remains a strong contender in the healthcare sector, bolstered by its reputation for inelastic demand in pharmaceuticals and a top-tier credit rating. With a solid dividend yield of 2.11% and impressive returns of 48.29% over the past year, it’s an attractive option for income-focused investors. Analysts have a median 12-month price target of $220, reflecting confidence in the company's stability and growth potential.
Pros:
- Strong dividend yield
- Consistent quarterly distributions
Cons:
- Legal uncertainties affecting stock performance
- Market volatility risks
Johnson & Johnson (JNJ) presents a viable investment opportunity for income-focused investors seeking stability in the healthcare sector, supported by its strong dividend yield and consistent historical returns. With its reputation for resilience and a favorable analyst outlook, this stock may be suitable for those looking to add a reliable, blue-chip company to their portfolio.